MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Su, T. T.
Right arrow Articles by Rawlings, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Su, T. T.
Right arrow Articles by Rawlings, D. J.
Molecular Interventions 2:141-144 (2002)
© 2002 American Society of Pharmacology and Experimental Therapeutics

Viewpoint

Emerging Roles for PKC Isoforms in Immune Cell Function

Thomas T. Su1, Beichu Guo2 and David J. Rawlings2,3

1 The Molecular Biology Institute, University of California, Los Angeles, CA 90095-1752, USA, and
2 Department of Immunology and
3 Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195, USA

SUMMARY

Two publications by Mecklenbräuker et al. and Miyamoto et al. describe an essential role for protein kinase C{delta} (PKC{delta}) in the development of immune tolerance, and suggest that PKC{delta} also participates in mechanisms that prevent autoimmunity. Su, Guo, and Rawlings discuss these observations within the larger context of determining specific functions for individual isoforms of PKC in B and T lymphocytes, and the careful control these proteins exert in maintaining proper lymphocyte activation and tolerance.




This article has been cited by other articles:


Home page
 Ann OncolHome page
F. Morschhauser, J. F. Seymour, H. C. Kluin-Nelemans, A. Grigg, M. Wolf, M. Pfreundschuh, H. Tilly, J. Raemaekers, M. B. van 't Veer, N. Milpied, et al.
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
Ann. Onc., February 1, 2008; 19(2): 247 - 253.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
E. Corsini, M. Racchi, E. Sinforiani, L. Lucchi, B. Viviani, G. E. Rovati, S. Govoni, C. L. Galli, and M. Marinovich
Age-related decline in RACK-1 expression in human leukocytes is correlated to plasma levels of dehydroepiandrosterone
J. Leukoc. Biol., February 1, 2005; 77(2): 247 - 256.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.